ARTICLE | Company News
GlycoRegImmune, RxMD deal
July 4, 2011 7:00 AM UTC
The companies partnered to develop new treatments using GlycoRegImmune's natural killer (NK) T cell targeted technologies for yet to be determined inflammatory, autoimmune and neurodegenerative diseases. RxMD is a strategic management organization that will engage operational vendors, including CROs, to help develop and identify regulatory pathways for GlycoRegImmune's technology. Details were not disclosed. ...